多西环素暴露后预防处方策略对细菌性性传播感染发病率的影响
该研究利用2015—2020年一家LGBTQ健康中心的电子健康记录,对10546名男男性行为者、跨性别女性及出生时指定男性别的非二元人群,模拟10种多西环素暴露后预防处方策略对细菌性性传播感染诊断的影响。结果显示,对所有个体处方可避免71%的诊断(NNT=3.9),对HIV暴露前预防使用者或HIV感染者处方可避免60%(NNT=2.9),在性传播感染诊断后12个月内处方可避免39%(NNT=2.4)。基于性传播感染史的处方策略效率最高但预防的诊断数较少。
要点
- 对所有个体处方多西环素暴露后预防可避免71%的细菌性性传播感染诊断,NNT=3.9。
- 对HIV暴露前预防使用者或HIV感染者处方可避免60%的诊断,NNT=2.9。
- 在性传播感染诊断后12个月内处方可避免39%的诊断,NNT=2.4,使用多西环素暴露后预防者比例降至38%。
核心结论
- 对患有性传播感染者,尤其是同期或重复感染者,处方多西环素暴露后预防可避免相当比例的所有性传播感染诊断。
- 最高效的处方策略基于性传播感染史而非HIV状态或HIV暴露前预防使用。
研究设计与样本
- 使用2015—2020年一家LGBTQ健康中心的电子健康记录,纳入10546名男男性行为者、跨性别女性及出生时指定男性别的非二元人群,均至少接受2次性传播感染检测(衣原体、淋病、梅毒),94%为男男性行为者。
- 定义10种基于HIV暴露前预防使用、HIV状态或性传播感染史的多西环素暴露后预防处方策略,在假设符合处方标准者接受多西环素暴露后预防的反事实场景中估计使用情况和避免的性传播感染诊断,假设使用期间性传播感染率按临床试验疗效估计降低。
主要发现
- 总体任何性传播感染率为35.9/100人年。
- 对所有个体处方多西环素暴露后预防可避免71%的性传播感染诊断,NNT=3.9。
- 对HIV暴露前预防使用者/HIV感染者(占个体52%/12%)处方可避免60%的性传播感染诊断,NNT=2.9。
- 在性传播感染诊断后12个月内处方多西环素暴露后预防可使使用多西环素暴露后预防者比例降至38%,并避免39%的性传播感染诊断,NNT=2.4。
- 在同期或重复性传播感染后处方可使效率最大化(NNT最低)但预防的性传播感染诊断较少。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Doxycycline post-exposure prophylaxis (doxyPEP) reduces bacterial sexually transmitted infection (STI) incidence in people with HIV (PWH) or using HIV preexposure prophylaxis (PrEP). Given concerns about widespread antibiotic use, we identified doxyPEP prescribing strategies to minimize use while maximizing impact on STIs. METHODS: We used electronic health records of gay and bisexual men (GBM), transgender women, and non-binary people assigned male sex at birth with ≥2 STI tests (chlamydia, gonorrhea, syphilis) at an LGBTQ-focused health center during 2015-2020. We defined 10 hypothetical doxyPEP prescribing strategies based on PrEP use, HIV status, or STI history. We estimated doxyPEP use and STI diagnoses averted in counterfactual scenarios in which people meeting prescribing criteria received doxyPEP, assuming STI rates during use would have been reduced by clinical trial efficacy estimates. RESULTS: Among 10,546 individuals (94% GBM), rate of any STI was 35.9/100 person-years. Prescribing doxyPEP to all individuals would have averted 71% of STI diagnoses (number needed to treat for one year to avert one STI diagnosis, NNT = 3.9); prescribing to PrEP users/PWH (52%/12% of individuals) would have averted 60% of STI diagnoses (NNT = 2.9). Prescribing doxyPEP for 12 months after STI diagnosis would have reduced the proportion using doxyPEP to 38% and averted 39% of STI diagnoses (NNT = 2.4). Prescribing after concurrent or repeated STIs would have maximized efficiency (lowest NNTs) but prevented fewer STIs. CONCLUSIONS: Prescribing doxyPEP to individuals with STIs, particularly concurrent or repeated STIs, could avert a substantial proportion of all STI diagnoses. The most efficient prescribing strategies are based on STI history rather than HIV status or PrEP use.
引用
- Traeger MW, Mayer KH, Krakower DS, et al. Potential impact of doxycycline post-exposure prophylaxis prescribing strategies on incidence of bacterial sexually transmitted infections. Clin Infect Dis. 2023. PMID: 37595139. doi:10.1093/cid/ciad488
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。